Radoslav Goldman's laboratory is funded by the Department of Defense to carry out a case control study evaluating the association of prostate cancer risk with deficiency in DNA repair capacity. Several measure of DNA repair including comet assay are used to compare DNA repair capacity in newly diagnosed prostate cancer patients and age matched healthy controls. The study is designed to evaluate difference in Caucasian and African American men who have twice the risk of prostate cancer. The study established a repository of clinical specimen from approximately 300 patients that is used for translational studies of prostate cancer. Peptides and glycans in patient blood are examined as markers for early detection complementary to the prostate specific antigen (PSA), the currently used clinical marker.